Clinical Trial Update: Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers [Phase 2]

View source ↗

Summary

This is a Phase 2, single-arm neoadjuvant trial of dostarlimab for stage II–III deficient mismatch repair colon cancers, currently recruiting. The study is spon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer

Drugs mentioned

• Dostarlimab (Jemperli) (dostarlimab)

Snippet

Sponsor: University of Iowa | Conditions: Colon Cancer, dMMR Colorectal Cancer | Phase 2 | Status: RECRUITING